4Druker BJ,Guilhot F,O'Brien SG,et al.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N Engl J Med,2006,355:2408-2417.
5Hochhaus A,Druker B,Sawyers C,et al.Favorable long-term followup results over 6 years for response,survival,and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.Blood,2008,111:1039-1043.
6Baccarani M,Rosti G,Castagnetti F,et al.Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk,Philadelphia-positive chronic myeloid leukemia:a European Leukemia Net Study.Blood,2009,113:4497-4504.
7Hochhans A,O'Brien SG,Guilhot F,et al.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia,2009,23:1054-1061.
8Guiloht F,Larson RA,Obrien SG.Time to CCyR does not affect longterm outcomes for patients on imatinib therapy.Blood,2007,110 Abst.27.
9Druker BJ,Talpaz M,Resta DJ,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med,2001,344:1031-1037.
10Quint ás-Cardama A,Kantarjian HM,Cortes JE.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Cancer Control,2009,16:122-131.
